Procept BioRobotics CEO Buys 23,900 Shares Amid 48% Stock Decline. What Does This Tell Investors?
Wood's $498,000 purchase through a trust vehicle expands his beneficial stake to 338,103 shares as the medical robotics firm navigates losses despite $337.3 million in trailing revenue.
Overview
Larry L. Wood, the President and CEO of Procept BioRobotics Corporation (NASDAQ:PRCT), reported an indirect purchase of 23,900 shares of common stock on August 7, 2026. SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($20.85); post-transaction value based on August 7, 2026 market close ($20.41).
Details
Procept BioRobotics is a San Jose-based medical device manufacturer with 888 employees operating in the surgical robotics sector. The company generated $337.3 million in trailing twelve month (TTM) revenue while operating at a net loss of $109.8 million, reflecting the capital-intensive nature of robotic surgical technology development and market expansion. Procept's competitive differentiation centers on its proprietary Aquablation technology platform and image-guided robotic system, which addresses a significant clinical need in minimally invasive urological procedures.
Source
Originally published at www.fool.com.